It’s Time to Rethink Channel Strategy for Oral Oncolytics

Today’s guest post comes from Akin Odutola, Senior Vice President, Specialty and Branded Product Access, Strategic Global Sourcing, at AmerisourceBergen. Akin discusses the challenges facing patients treated with oral oncology drugs in community practices and health systems. He then describes AmerisourceBergen’s solution for coordinating patient care and providing aggregated specialty pharmacy data from healthcare providers. To learn more, download Rethink: Channel Strategy for Oral Oncolytics. Read on for Akin’s insights. Read more » Copyright © 2006-2018 Pembroke Consulting, Inc. d/b/a Drug Channels Institute. Drug Channels® is a registered trademark of Pembroke Consulting, Inc. This Feed is for personal non-commercial use … Continue reading It’s Time to Rethink Channel Strategy for Oral Oncolytics

Closing The Loop on Patient Engagement: Overcoming the PA Washout

Pharma brands invest heavily in sales and marketing tactics aimed at convincing physicians to prescribe their product. Even when successful, these efforts represent only a first step in realizing more prescriptions that actually get dispensed. Particularly when a prescription requires prior auth Powered by WPeMatico Continue reading Closing The Loop on Patient Engagement: Overcoming the PA Washout

Preorder Now: Our 2018–19 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors

On October 9, 2018, Drug Channels Institute will release The 2018–19 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors. It’s the ninth edition of our annual evaluation of the economic and business realities driving U.S. drug distribution. This definitive, nonpartisan resource remains the most comprehensive tool for analyzing the industry. The 2018-19 edition has been thoroughly updated and revised with the latest information. This year, we are providing you with the opportunity to preorder the 2018-19 edition at special discounted prices. This means that you can be among the first to access our new report. Those who preorder will receive … Continue reading Preorder Now: Our 2018–19 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors

FDA Launches Major Push for New Antimicrobials

The critical need for new medicines to combat infectious diseases that fail to respond to current medical treatment is prompting FDA to join with other federal health agencies and the biomedical research community to advance the science, regulatory policies and reimbursement strategies to suppor Powered by WPeMatico Continue reading FDA Launches Major Push for New Antimicrobials

Copay Accumulator Update: Widespread Adoption As Manufacturers and Maximizers Limit Patient Impact

In January, I alerted you to an important new benefit design trend in Copay Accumulators: Costly Consequences of a New Cost-Shifting Pharmacy Benefit. It is by far the most widely read article ever published on Drug Channels. New data from Zitter Health insights (ZHI) suggest that these programs are widely used. Nearly one-third of commercially-insured lives are enrolled in plans that have implemented copay accumulator adjustment or closely-related copay maximizers. (We explain the benefit design math behind maximizers below.) ZHI also found that a surprising number of plans are already set up to use these programs, but have not done so … Continue reading Copay Accumulator Update: Widespread Adoption As Manufacturers and Maximizers Limit Patient Impact

GTN 2018 – CBI’s Gross-to-Net Summit

GTN 2018 – CBI’s Gross-to-Net Summit November 15-16, 2018 | Philadelphia, PA www.cbinet.com/gtn With the total value of off-invoice discounts and rebates increasing over the last few years, it is pivotal that pharmaceutical and biotech manufacturers stay on the forefront of gross-to-net management. CBI’s GTN Summit, now in the 8th year, is the first step toward positioning your organization for success in the years ahead. You can download the complete agenda here. The meeting is coming up on November 15-16 at the Hilton Philadelphia at Penn’s Landing and features expert perspectives from companies such as Adamas, Amgen, Amneal/Impax, Astellas, BMS, … Continue reading GTN 2018 – CBI’s Gross-to-Net Summit

Artificial Intelligence (AI): How Specialty Pharmacies Are Making Medication Package Management More Predictable, Scalable, and Efficient

Today’s guest post comes from Scott Knight, Founder and President at ParcelShield. Scott explains how artificial intelligence is being used to improve medication package management in specialty pharmacy. It’s an intriguing look at the application of next-generation technologies that can benefit patients. To learn more about AI in specialty pharmacy, download ParcelShield’s free white paper Man Vs. Machine: How Artificial Intelligence (AI) Makes Specialty Parcel Management More Predictable, Scalable, and Efficient. Read on for Scott’s insights. Read more » Copyright © 2006-2018 Pembroke Consulting, Inc. d/b/a Drug Channels Institute. Drug Channels® is a registered trademark of Pembroke Consulting, Inc. This … Continue reading Artificial Intelligence (AI): How Specialty Pharmacies Are Making Medication Package Management More Predictable, Scalable, and Efficient

Updated Part B Data: Hospitals Are Displacing Physician Offices Even Faster Than We Thought

The Medicare Payment Advisory Commission (MedPAC), the independent agency that advises Congress on the Medicare program, recently released its latest annual report: June 2018 Data Book: Health Care Spending and the Medicare Program. It’s a charming, 216-page data romp through all aspects of Medicare. Chapter 10 focuses on prescription drugs. This year’s report provides new and revised details about the locations where Part B buy-and-bill spending occurs. As you will see below, physician offices account for a smaller share of spending than what we previously reported. Hospital outpatient departments account for a higher share. What’s more, the new MedPAC data … Continue reading Updated Part B Data: Hospitals Are Displacing Physician Offices Even Faster Than We Thought